Multiple Sclerosis

‘All the data we have right now suggests alcohol causes more harm than cannabis. That’s the hypothesis.’

A long-awaited study into Paolo Zamboni’s treatment yields disappointment for most sufferers—yet hope of relief for a few

Results from a key Canadian study into venoplasty for MS appear to have been prematurely released, leaving questions

The stem cell treatment for MS greeted as a “cure” is a breakthrough for five per cent of people with MS. What about the other 95 per cent?

Anne Kingston on how the criticism levelled at Kirsty Duncan over a controversial MS treatment is surprisingly unscientific

Two new studies suggest a potential game-changer in how scientists understand of the brain, which could advance research on MS and Alzheimer’s

The cheeky rebranding of multiple sclerosis in Canada raises the fair question: why are rates so high here?

Anne Kingston on the MS research that captured headlines in 2013

Last week’s shut-down of the Albany, NY clinical trial investigating CCSVI treatment due to lack of patient enrollment is a big set-back on a number of fronts. It’s bad news for the Saskatchewan government, which allocated $2.2 million and recruited patients to travel to the U.S.—and a  blow for those who’d taken part in the trial or were lined up to go. But, like all failures, it’s instructive.

Anne Kingston explains why we’ve reached the WTF moment in CCSVI research

Patients are left with costs as discredited MS therapy circles the drain, writes Colby Cosh

Internal documents show why Canada has not kept its promise to accelerate contentious clinical trials for MS